These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Sormani MP; Rovaris M; Comi G; Filippi M Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123 [TBL] [Abstract][Full Text] [Related]
31. Corticomotoneuronal integrity and adaptation in spinal muscular atrophy. Farrar MA; Vucic S; Johnston HM; Kiernan MC Arch Neurol; 2012 Apr; 69(4):467-73. PubMed ID: 22491191 [TBL] [Abstract][Full Text] [Related]
32. Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Calabrese M; Rinaldi F; Mattisi I; Grossi P; Favaretto A; Atzori M; Bernardi V; Barachino L; Romualdi C; Rinaldi L; Perini P; Gallo P Neurology; 2010 Jan; 74(4):321-8. PubMed ID: 20101038 [TBL] [Abstract][Full Text] [Related]
33. Multislice brain myelin water fractions at 3T in multiple sclerosis. Oh J; Han ET; Lee MC; Nelson SJ; Pelletier D J Neuroimaging; 2007 Apr; 17(2):156-63. PubMed ID: 17441837 [TBL] [Abstract][Full Text] [Related]
34. Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis. Rossi S; Mancino R; Bergami A; Mori F; Castelli M; De Chiara V; Studer V; Mataluni G; Sancesario G; Parisi V; Kusayanagi H; Bernardi G; Nucci C; Bernardini S; Martino G; Furlan R; Centonze D Mult Scler; 2011 Nov; 17(11):1301-12. PubMed ID: 21677024 [TBL] [Abstract][Full Text] [Related]
35. Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Vucic S; Cheah BC; Kiernan MC Exp Neurol; 2009 Nov; 220(1):177-82. PubMed ID: 19716820 [TBL] [Abstract][Full Text] [Related]
36. Assessment of cortical excitability using threshold tracking techniques. Vucic S; Howells J; Trevillion L; Kiernan MC Muscle Nerve; 2006 Apr; 33(4):477-86. PubMed ID: 16315324 [TBL] [Abstract][Full Text] [Related]
37. Differences in diffusion tensor imaging-derived metrics in the corpus callosum of patients with multiple sclerosis without and with gadolinium-enhancing cerebral lesions. Braley TJ; Lee YH; Mohan S; Segal BM; Berini S; Srinivasan A J Comput Assist Tomogr; 2012; 36(4):410-5. PubMed ID: 22805669 [TBL] [Abstract][Full Text] [Related]
38. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Bates D Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678 [TBL] [Abstract][Full Text] [Related]
39. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox? Strasser-Fuchs S; Enzinger C; Ropele S; Wallner M; Fazekas F Mult Scler; 2008 Mar; 14(2):205-11. PubMed ID: 17986507 [TBL] [Abstract][Full Text] [Related]
40. MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction. Anderson VM; Fisniku LK; Altmann DR; Thompson AJ; Miller DH Mult Scler; 2009 Jul; 15(7):811-7. PubMed ID: 19465449 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]